Cargando…

Long Term Follow up of Patients With Primary Obstetric Antiphospholipid Syndrome

Introduction: Primary obstetric antiphospholipid syndrome (OAPS) is defined by specific morbidities and/or losses of pregnancy in the presence of persistent antiphospholipid antibodies (aPL). This variant of APS is usually treated during pregnancy and the post-partum period. Data on occurrence of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Niznik, Stanley, Rapoport, Micha J., Avnery, Orly, Lubetsky, Aharon, Shavit, Ronen, Ellis, Martin H., Agmon-Levin, Nancy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068935/
https://www.ncbi.nlm.nih.gov/pubmed/35529433
http://dx.doi.org/10.3389/fphar.2022.824775
_version_ 1784700325849989120
author Niznik, Stanley
Rapoport, Micha J.
Avnery, Orly
Lubetsky, Aharon
Shavit, Ronen
Ellis, Martin H.
Agmon-Levin, Nancy
author_facet Niznik, Stanley
Rapoport, Micha J.
Avnery, Orly
Lubetsky, Aharon
Shavit, Ronen
Ellis, Martin H.
Agmon-Levin, Nancy
author_sort Niznik, Stanley
collection PubMed
description Introduction: Primary obstetric antiphospholipid syndrome (OAPS) is defined by specific morbidities and/or losses of pregnancy in the presence of persistent antiphospholipid antibodies (aPL). This variant of APS is usually treated during pregnancy and the post-partum period. Data on occurrence of thrombotic event during long term follow-up of OAPS patients is limited. Methods: A multi-centre retrospectively cohort of female patients with primary APS (pAPS) was assembled during 2004–2019. Patients were grouped according to disease presentation as pure OAPS or thrombotic APS (tAPS) for those presenting with thrombosis. Clinical and serological data were compared between groups. Results: Of 219 pAPS female patients 67 (30.6%) were diagnosed with OAPS and 152 (69.4%) with tAPS. During >10 years of follow-up 24/67 (35.8%) OAPS and 71/152 (50%) tAPS suffered a new thrombotic event (p = 0.06), while obstetric morbidity was more likely in the OAPS group (31.3 vs. 10.5%, p < 0.001) respectively. Among patients with OAPS at presentation heart valve disease and the presence of ANA were related to thrombosis following diagnosis (25 vs. 4.7%, p = 0.02; and 45.8 vs. 20.8%, p = 0.04 respectively). Conclusion: Thrombotic event following diagnosis were common among female patients with pAPS regardless of disease presentation. Heart valve disease and ANA positivity may be risk factors for thrombosis during follow-up of patients presenting with pure OAPS.
format Online
Article
Text
id pubmed-9068935
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90689352022-05-05 Long Term Follow up of Patients With Primary Obstetric Antiphospholipid Syndrome Niznik, Stanley Rapoport, Micha J. Avnery, Orly Lubetsky, Aharon Shavit, Ronen Ellis, Martin H. Agmon-Levin, Nancy Front Pharmacol Pharmacology Introduction: Primary obstetric antiphospholipid syndrome (OAPS) is defined by specific morbidities and/or losses of pregnancy in the presence of persistent antiphospholipid antibodies (aPL). This variant of APS is usually treated during pregnancy and the post-partum period. Data on occurrence of thrombotic event during long term follow-up of OAPS patients is limited. Methods: A multi-centre retrospectively cohort of female patients with primary APS (pAPS) was assembled during 2004–2019. Patients were grouped according to disease presentation as pure OAPS or thrombotic APS (tAPS) for those presenting with thrombosis. Clinical and serological data were compared between groups. Results: Of 219 pAPS female patients 67 (30.6%) were diagnosed with OAPS and 152 (69.4%) with tAPS. During >10 years of follow-up 24/67 (35.8%) OAPS and 71/152 (50%) tAPS suffered a new thrombotic event (p = 0.06), while obstetric morbidity was more likely in the OAPS group (31.3 vs. 10.5%, p < 0.001) respectively. Among patients with OAPS at presentation heart valve disease and the presence of ANA were related to thrombosis following diagnosis (25 vs. 4.7%, p = 0.02; and 45.8 vs. 20.8%, p = 0.04 respectively). Conclusion: Thrombotic event following diagnosis were common among female patients with pAPS regardless of disease presentation. Heart valve disease and ANA positivity may be risk factors for thrombosis during follow-up of patients presenting with pure OAPS. Frontiers Media S.A. 2022-04-21 /pmc/articles/PMC9068935/ /pubmed/35529433 http://dx.doi.org/10.3389/fphar.2022.824775 Text en Copyright © 2022 Niznik, Rapoport, Avnery, Lubetsky, Shavit, Ellis and Agmon-Levin. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Niznik, Stanley
Rapoport, Micha J.
Avnery, Orly
Lubetsky, Aharon
Shavit, Ronen
Ellis, Martin H.
Agmon-Levin, Nancy
Long Term Follow up of Patients With Primary Obstetric Antiphospholipid Syndrome
title Long Term Follow up of Patients With Primary Obstetric Antiphospholipid Syndrome
title_full Long Term Follow up of Patients With Primary Obstetric Antiphospholipid Syndrome
title_fullStr Long Term Follow up of Patients With Primary Obstetric Antiphospholipid Syndrome
title_full_unstemmed Long Term Follow up of Patients With Primary Obstetric Antiphospholipid Syndrome
title_short Long Term Follow up of Patients With Primary Obstetric Antiphospholipid Syndrome
title_sort long term follow up of patients with primary obstetric antiphospholipid syndrome
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068935/
https://www.ncbi.nlm.nih.gov/pubmed/35529433
http://dx.doi.org/10.3389/fphar.2022.824775
work_keys_str_mv AT niznikstanley longtermfollowupofpatientswithprimaryobstetricantiphospholipidsyndrome
AT rapoportmichaj longtermfollowupofpatientswithprimaryobstetricantiphospholipidsyndrome
AT avneryorly longtermfollowupofpatientswithprimaryobstetricantiphospholipidsyndrome
AT lubetskyaharon longtermfollowupofpatientswithprimaryobstetricantiphospholipidsyndrome
AT shavitronen longtermfollowupofpatientswithprimaryobstetricantiphospholipidsyndrome
AT ellismartinh longtermfollowupofpatientswithprimaryobstetricantiphospholipidsyndrome
AT agmonlevinnancy longtermfollowupofpatientswithprimaryobstetricantiphospholipidsyndrome